Puma Biotech (PBYI) Tops Q3 EPS by 13c, Misses on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to Puma Biotech (PBYI) Tops Q3 EPS by 13c, Misses on Revenue

Puma Biotechnology Reports Third Quarter 2024 Financial Results

November 7, 2024 4:05 PM EST

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023.

Product revenue, net consists entirely of sales revenue from NERLYNX®, Pumas first commercial product. Product revenue, net in the third quarter of 2024 was $56.1 million, compared to $51.6 million in the third quarter of 2023. Product revenue, net in the first nine months of 2024 was $140.8 million, compared to $149.9 million in the first nine months of 2023.

Based... More